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Abstract
Background Little is known about the relation of adverse
drug reactions (ADRs) to self-use of medications.
Objective The aim of this study was to determine the
frequency and severity of ADRs related to self-medication
(ADR-SM) among emergency department (ED) patients
and to describe their main characteristics.
Methods A prospective, cross-sectional, observational
study was conducted over a period of 8 weeks (1 March to
20 April 2010), in the ED of 11 French academic hospitals.
Adult patients presenting to the ED during randomization
periods were included, with the exception of cases of self-
drug poisoning, inability to complete self-medication
questionnaire, or refusal. Clinical outcomes were assessed
as well as history of self-medication behaviours and all
drugs taken. All doubtful files and those related to ADR-
SM were systematically reviewed by an expert committee.
Results A total of 3,027 of 4,661 patients presenting to
the ED met the inclusion criteria. Of these, 84.4 %
declared a self-medication behaviour, 63.7 % took at least
one non-prescribed drug during the previous 2 weeks and
59.9 % took a prescribed medication. A total of 296
patients experienced an ADR (9.78 %), of which 52
(1.72 %) were related to self-medication. Those ADRs
related to self-medication included prescribed drugs
(n = 19), non-prescribed drugs (n = 17), treatment dis-
continuation (n = 14), and interactions between non-pre-
scribed and prescribed drugs (n = 2). The ADRs attributed
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to non-prescribed drugs represented 1 % of all patients taking
non-prescribed drugs (n = 1,927). ADR severity was signifi-
cantly lower for those related to self-medication (p = .032).
Conclusion Self-medication is frequent; its potential
toxicity should not be neglected, taking into account the
rate of adverse drug reactions in about 1 % of ED patient.
1 Background
Drug-related problems are an important cause of morbidity
and mortality and a significant burden on healthcare
resources. A high rate of adverse drug reactions (ADRs)
has been demonstrated in hospitalized patients [1–4],
potentially leading to death. As patients with severe or
acute unexpected symptoms frequently present to emer-
gency departments (EDs), some epidemiological studies of
ADRs have been successfully conducted in this setting,
showing that approximately 10–17 % of ED visits were
related to an ADR [5, 6].
The definition of self-medication is still debated. According
to the National Library of Medicines’ MeSH (Medical Subject
Headings) database, self-medication refers to self-adminis-
tration of a medication not prescribed by a physician, or in a
manner not directed by a physician. Furthermore, the WHO
defines self-medication as the selection and use of medicines
by individuals to treat self-recognized illnesses or symptoms
[7], and cites self-medication as a common problem leading to
incorrect use of medicine [8]. Therefore, a patient-based
approach of self-medication should include all modalities of
self-use of drugs, whether previously prescribed or not. This
study was based on such a patient-based approach.
Despite numerous studies on ADRs, there are no available
data informing us about the rate of ADRs directly related to
self-medication (ADR-SM). As such, the risk related to cur-
rent self-medication behaviours is under-investigated. In the
ED-specific context, previously published studies [5, 6] have
not focused on the link between self-medication and ADRs.
No data on the rate and severity of ADRs related to self-
medication in this setting are available.
To determine the prevalence ratio and severity of ADR-
SM in the ED population, we designed a multicentre,
ED-based, cross-sectional survey in 11 French hospitals. We
also attempted to identify the characteristics of ED patients
and their drugs associated with ADRs and ADR-SM.
2 Methods
2.1 Study Design
During the 8-week period from 1 March until 20 April
2010, a prospective, cross-sectional, observational study
was conducted in the ED of 11 French academic hospitals
distributed throughout the country.
Definition of self-medication in the study protocol:
• To take drugs without relevant prescription (sold
without prescription, rest of an ancient prescription or
prescribed for another person)
• A self-modification of treatment
• A self-discontinuation of treatment
2.2 Approvals
The study protocol and patient informed consent proce-
dures were approved by the Ethics Committee (St. Etienne
CHU on 10 February 2008), and the Committee on Infor-
mation in Health Research (CCTIRS/CNIL), according to
French rules in clinical research.
2.3 Sampling and Randomization
A high volume of visits in participating EDs precluded
uninterrupted prospective screening for inclusion through-
out the study period. Additionally, as rates of hourly ED
visits varied markedly within each day and from one day to
another, we defined 13 time slots a priori covering the 24-h
day as follows: 10 time slots of 1 h (from 10:00 am to
2:00 pm and from 5:00 pm to 11:00 pm), one time slot of 8
hours (from 11:00 pm to 7:00 am) and two time slots of 3 h
(from 7:00 am to 10:00 am and from 2:00 pm to 5:00 pm).
Subsequently, we randomly allocated these 13 predefined
time slots throughout the 8 weeks of the study period for
each participating ED. Randomization was done with
computer-generated codes prior to the study enrolment
period by our clinical research unit, which was not
involved in data collection or patient care. Allocations
were disclosed to research staff in every participating ED
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just prior to the study enrolment period. This method was
designed to limit the potential for sampling bias. Addi-
tionally, patient demographics (age, gender and acute
severity triage score) [9] were collected from administra-
tive data of each participating centre over the same 8-week
enrolment period. These data were compared with the
overall study population to verify the representativeness of
the ED population studied.
2.4 Patient Enrolment
All adult patients presenting to participating EDs during
one of the predefined time slots were eligible for study
enrolment. On entry, they were informed with a specific
form about the study and the opportunity to participate.
Medical or pharmacy students (hereafter designated as
research staff) in every participating ED were specifically
trained to screen candidates for study enrolment, using
standardized screening forms. Consenting patients were
subsequently included in the absence of exclusion criteria.
2.5 Exclusion Criteria
The following were precluded because we aimed to
describe self-medication behaviour and unintentional
related ADRs: (i) patients unable to participate because of
cognitive impairment, neuropsychiatric disorders, language
barriers or having presented with an unstable medical ill-
ness in the absence of a near relative who could answer for
them; (ii) patients presenting for attempting suicide; and
(iii) declining study participate (a written information form
was submitted to patients and/or their relatives at the time
of their admission to the ED). In each instance, the reason
for exclusion was systematically recorded.
2.6 Variables and Data Collection
Self-medication behaviours were explored by a standard-
ized questionnaire that had been previously built, imple-
mented and tested in one centre [10] (see electronic
supplementary material). This questionnaire is divided into
two parts. The first part consists of a set of 20 closed-ended
questions exploring all indications and dimensions of self-
medication. The second part collects the characteristics of
each medication cited by the patient during the first part
(dosage, time between last dose and the ED visit, origin).
The method of data collection during the ED evaluation
was then tested in three voluntary centres, which included
standardized interviews of patients and/or their surrogates,
as well as review of the medical record (i.e. physician notes
and orders, laboratory reports, nursing notes, discharge
instructions and ongoing prescriptions). Special attention
was paid to all medications taken within 2 weeks prior to
patient enrolment, including prescribed and non-prescribed
drugs. All data were entered using online electronic case
report forms (e-CRF), which allowed for real-time assess-
ment of data completeness and patient follow-up. Data
collection was performed by the local research staff, which
was monitored by a clinical research pharmacist and
supervised by the investigators.
2.7 Adverse Drug Reaction (ADR) Identification
Process
The primary outcome was the diagnosis of ADR-SM and
the identification of clinical and biological findings related
to the effect of the drug(s). The investigators reviewed all
cases to identify ADRs in each study centre, based on
VIDAL dictionary (French book summarizing the charac-
teristics of all medications, including pharmacology,
adverse effects and drug-drug interactions). The local
investigators were helped by the Naranjo scale [11] for
drug causality assessment. Nevertheless, whatever could be
the result of this score, they were asked to transmit all
clinically relevant cases. The severity of the ADRs was
assessed according to the Common Terminology Criteria
for Adverse Events (CTCAE) [12], as (A) spontaneous
regression; (B) regression after symptomatic treatment;
(C) hospitalization with no life-threat; (D) life-threatening
risk; and (E) death. The diagnosis of ADR and the drug
causality assessment were then documented in the e-CRF.
If necessary, notification of cases of drug toxicity was
provided to the pharmacovigilance regional centre at the
discretion of the local investigator.
All contentious issues transmitted by local investigators,
every ADR-SM case (whether contentious or not), and
some randomly assigned files were reviewed by an expert
committee comprised of therapeutics professors, clinical
pharmacists and emergency physicians, whose meetings
and minutes were managed by the clinical research phar-
macist. Furthermore, the entire database was scrutinized by
the clinical research pharmacist in order to detect each case
potentially related to an ADR; the expert committee was
asked to assess such cases and to confirm drug causality (in
order to validate the main outcome). Every local investi-
gator was also asked to verify each subject file and to
transmit all useful information regarding the possibility of
an ADR to the expert committee. This committee was
finally able to resolve each contentious case, and to vali-
date the entire database. Last, the expert committee
determined, for each ADR-SM case, the type of self-
medication leading to the adverse event: self-modification
of a prescribed treatment, discontinuation of treatment,
non-prescribed drugs, or a drug interaction with non-pre-
scribed drugs (i.e. self-prescription).
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2.8 Grouping of Data
The diagnosis of the chief complaint and that of the ADR
were first encoded to the International Classification of
Diseases, 10th revision (ICD-10). To further improve
grouping, data were re-coded using a standardized classi-
fication designed by the Socie´te´ Franc¸aise de Me´decine
d’Urgence (SFMU: French Society of Emergency Medi-
cine) [13]. All drugs cited by patients, whether prescribed
or not, were encoded to the Anatomical Therapeutic
Chemical (ATC) classification system [14]. Medications
not covered by the ATC were encoded as ‘Z’ (herbal
medicines, vitamins, food supplements, calcium, magne-
sium, diosmine, anti-nausea or anti-diarrhoea pills, some
medicines for constipation, balms and topical emollients,
topical medicines for common cold, some anti-tussive
syrups, omega 3 …).
2.9 Statistical Analysis of Data
Sample size: considering a rate of ADR-SM possibly not
over 1 % of ED patients (personal data), we targeted the
enrolment of approximately 5,000 patients (in order to
observe a minimum of 30 cases, alpha risk 0.05, power
[0.80).
Patient characteristics are presented as the mean and
frequency with 95 % confidence intervals (CIs) using
Jeffreys confidence limits for the binomial proportion. Chi-
square tests for qualitative variables or Student t tests for
quantitative variables were computed to determine if an
association exists between patients admitted with ADRs
and self-medication. A p-value of less than 0.05 was con-
sidered to be significant. In a second step, a multivariate
logistic regression analysis was used to predict whether or
not a patient had an ADR-SM based on significant char-
acteristics of the patients as determined by univariate
analysis. Analyses were carried out with SAS version 9.2
(SAS Institute Inc, Cary, NC, USA).
3 Results
3.1 Characteristics of the Study Population
During the randomization periods, 4,661 patients were
admitted to the ED. Among these, 35.1 % were not
included (Fig. 1), which was most often due to inability to
answer the self-medication standardized questionnaire.
Table 1 shows the comparison of the study population with
the total ED population during the study period. The
demographic data appeared relatively equivalent. Never-
theless, there was a significant difference in terms of
gender between the groups. Likewise, the acute severity
triage score was also different, whereby level 1 was
underrepresented and level 5 was overrepresented among
the study patients. The 3,027 study patients were 53.5 %
female (including 16 pregnant women) and had a median
age of 43 years (range 18–99). The chief complaint was
trauma in about one-third of the patients, with the other
most frequent complaints being abdominal pain, weakness
and cardiovascular diseases (Table 2).
3.2 Pharmaceutical Data
Of the patients included, 59.9 % took at least one pre-
scribed medication, and 63.7 % self-medicated during the
previous 2 weeks. Additionally, 84.1 % declared a self-
medication behaviour (Table 2). Of the 11,724 drugs taken
by the study population, 32.5 % were in a self-medication
manner, and the most frequent were analgesics (n = 2,184,
75 % self-medication). Among the 3,848 drugs used in
self-medication, origin was most frequently a non-pre-
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the pharmacy (50.5 %), followed by the rest of a previous
prescription (19.9 %) and the use of a conditional pre-
scription (14.5 %). Less frequent sources of self-medica-
tion were drugs supplied by relatives (5.3 %), the use of a
prescribed drug with self-modification of the dose or
duration (2.1 %), drugs purchased by mail or internet
(1.2 %) and other unspecified sources (6.5 %).
3.3 Frequency of ADRs Related to Self-Medication
(ADR-SM)
Of the entire cohort, 9.8 % (296/3,027) of patients expe-
rienced an ADR that was related to self-medication in 52
cases (Fig. 1). Depending on the population considered for
the denominator, the rate of ADR-SM could be expressed
as 17.6 % of patients experiencing an ADR (52/296),
1.7 % of the study population (52/3,027) or 2 % of patients
reporting a self-medicating behaviour (52/2,556).
– ADR-SM related to prescribed drugs (self-medication
behaviour): The type of self-medication leading to an
ADR was most frequently associated with prescribed
drugs, as a self-modification of a prescribed treatment
in 21 cases or discontinuation of treatment in 14 cases.
Finally, about two-thirds of ADR-SM are subsequent to
the patients’ own decision on prescribed treatment.
– ADR-SM related to non-prescribed drugs: The use of
non-prescribed drugs occurred in 16 cases of ADR-SM,
and drug interaction with non-prescribed drugs in 1
case (so non-prescribed drugs led to a total of 17 cases
of ADR-SM). The rate of ADRs related to non-
prescribed drugs was 32.7 % of ADR-SM, 5.7 % of
ADRs, and approximately 0.9 % among patients taking
non-prescribed drugs during the previous 2 weeks (17/
1,927).
3.4 Characteristics of ADR-SM in Comparison With
Other ADRs
Bleeding was the most frequent ADR diagnosed, but for
ADRs related to self-medication the diagnoses were most
frequently neurologic and psychiatric. The drugs most
frequently causative of ADRs were antithrombotics (class
B). For ADR-SM, drugs belonging to the nervous system
drugs (class N) accounted for more than half of the caus-
ative agents, of which analgesics (class N02) were signif-
icantly associated with ADR-SM. The severity of ADR-SM
was lower than that of other ADRs (Table 3). From the
multivariate analysis, young age and ATC class N could
both be considered as independent factors associated with
ADR-SM (Table 4).
4 Discussion
This epidemiological study showed that self-medication
could result in ADRs, representing about 1–2 % of ED
patients, depending on the type of self-medication and the
denominator considered. In comparison with ADRs related
to a medical prescription, ADR-SM more frequently
resulted in neurologic or psychiatrics side effects, and were
more frequently related to nervous system drugs (ATC
class N). The frequency and severity of ADRs seem to be
weaker when related to self-medication. Nevertheless,
these results should be carefully interpreted. The impor-
tance of the risk demonstrated here in the ED population
should be weighed against the potential benefit, which has
to be important enough to make the risk acceptable.
Several studies have confirmed that antithrombotic
agents, especially vitamin K inhibitors, are a common
cause of ADRs [2–4]. These data are confirmed in our
results; however, we have not observed ADR-SM related to
this class in the study population. We have observed that
Table 1 comparison of the study population with total emergency
department (ED) population during the study period
Study patients (%) ED population (%)a









Gender n = 3,027 n = 88,531 p = 0.01
Male 46.4 44.6
Female 53.5 55.3
CCMUb n = 2,104 n = 58,268 p \ 0.0001
Level 1 8.7 14.4
Level 2 59.4 59.4
Level 3 27.1 21.7
Level 4 4.1 2.7
Level 5 0.7 1.8
a The ED population data are the administrative data obtained for the
total ED population during the study period
b The French clinical classification of emergency patients, usually
used for care prioritization (9): Level 1: Clinical condition considered
as stable and decision of no further procedure in the emergency room;
Level 2: Level 1 and decision of further procedure in the emergency
room; Level 3: Clinical condition likely to worsen; Level 4: Life-
threatening risk and no decision of starting resuscitation procedures;
Level 5: Level 4 and decision of starting resuscitation procedures in
the emergency room
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the most common class associated with ADR-SM was
psycholeptic and analgesic drugs. The increasing con-
sumption of analgesic self-medication highlights the need
for information and prevention regarding the risks of OTC
medications [15], particularly as patients commonly
underrate the risks of ADR-SM [16]. Moreover, the high
frequency of ADR-SM associated with self-modification or
self-discontinuation of treatment advocates strongly for
patient education, especially for the use of psycholeptic
and antiepileptic drugs. Tracks for the analysis of ADR-SM
were proposed 2 decades ago to understand how they arise
[17], whereby the most commonly explored are factors
dependent on doctors, healthcare professionals and insti-
tutions. On the other hand, factors that appear linked to the
patient and to the doctor-patient relationship are lesser
studied. As a consequence, the patients’ therapeutic
behaviours and self-medication with non-prescribed drugs
must be examined to explore actual causes of ADRs.
Indeed, the individual’s assessment of illness and their
subsequent response to it are not so spontaneous, as these
result from learning (not only with professionals) that is
based on the representation of illness and medications [18].
This sociopsychological approach considers the patient
as greater in importance than the drug or the







Total no. of ADRs
n = 296
Diagnosis of ADR a
Neurologic diseases 34.6 [22.8–48.1] 8.6 [5.6–12.6] 13.2 [9.7–17.4]
Mental status change 17.3 [8.9–29.2] 2.1 [0.79–4.4] 4.7 [2.7–7.6]
Cardiovascular diseases 9.6 [3.8–19.8] 14.8 [10.7–19.6] 13.9 [10.3–18.1]
Weakness 7.7 [2.7–17.3] 4.9 [2.7–8.2] 5.4 [3.3–8.4]
Fall 7.7 [2.7–17.3] 7.8 [4.9–11.7] 7.8 [5.1–11.2]
Endocrine and metabolic diseases 5.8 [1.7–14.6] 11.9 [8.3–16.4] 10.8 [7.7–14.7]
Skin and soft tissues diseases 5.8 [1.7–14.6] 5.7 [3.3–9.2] 5.7 [3.5–8.8]
Hepato-gastrointestinal diseases 5.8 [1.7–14.6] 12.7 [9.0–17.3] 11.5 [8.2–15.5]
Bleeding 1.9 [0.21–8.6] 18.9 [14.3–24.1] 15.9 [12.1–20.4]
Infections 1.9 [0.21–8.6] 4.1 [2.1–7.2] 3.7 [2.0–6.3]
Others diseases 1.9 [0.21–8.6] 2.5 [1.0–5.0] 2.4 [1.1–4.6]
Coagulopathy 0 2.9 [1.3–5.6] 2.4 [1.1–4.6]
Haematological diseases 0 2.9 [1.3–5.6] 2.4 [1.1–4.6]
Respiratory diseases 0 0.4 [0.04–1.9] 0.3 [0.04–1.6]
ADR severity 0.032
A: Spontaneous regression 34.6 [22.8–48.1] 18.9 [14.3–24.1] 21.6 [17.2–26.6]
B: Regression after symptomatic treatment 28.9 [17.9–42.1] 30.3 [24.8–36.3] 30.1 [25.1–35.5]
C: Hospitalization with no life-threat 36.5 [24.5–50.1] 44.7 [38.5–50.9] 43.2 [37.7–48.9]
D: Life-threatening risk 0 6.2 [3.6–9.7] 5.1 [3.0–8.0]
E: Death 0 0 0
ATC of causative drugs n = 68 n = 404 n = 472
C, Cardiovascular system drugs 8.8 [3.8–17.3] 27.5 [23.3–32.0] 0.001 24.8 [21.1–28.8]
B, Blood drugs—antithrombotics and
platelet aggregation inhibitors
0 19.3 [7.3–15.0] \0.0001 16.5 [13.4–20.1]
N, Nervous sytem drugs (N02–analgesics excluded) 55.9 [44.0–67.2] 20.1 [16.4–24.2] \0.0001 25.2 [21.5–29.3]
N02–analgesics 19.1 [11.2–29.6] 5.7 [3.7–8.3] 0.0001 7.6 [5.5–10.3]
a Test not performed because the conditions of application were not met
ADRs adverse drug reactions, ADR-SM ADRs related to self-medication, ADR-no SM ADRs not related to self-medication, ATC Anatomical
Therapeutic Chemical
Table 4 Characteristics explicating adverse drug reactions related to
self-medication
Characteristics Odds ratio 95 % CI
Age (C65 years vs. 18–64 years) 0.12 0.05–0.30
Gender 0.75 0.38–1.51
Nervous system drugs 4.07 1.74–9.47
Number of drugs taken (C5 vs. 0–4) 0.65 0.31–1.36
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professional. Therefore, the definition of self-medication
should not be restricted to OTC drugs. In a national
French report [19], self-medication was recognized as a
behaviour rather than as a class of medications (specifi-
cally OTC, as it is recognized in the UK). This approach
allows for the inclusion of all therapeutic choices decided
by the patient in the definition of self-medication and
self-medicating behaviour. However, scientific data
regarding self-medication are, to date, rare in the medical
literature, and they mostly concern OTC drugs and focus
on pharmaceutical aspects of self-medication [20, 21].
Moreover, data that are available tend to be quantitative
consumption data issued from industry and pharmacist
surveys regarding only OTC medicines [ISM Health,
AESGP (Association Europe´enne des Spe´cialite´s Phara-
maceutiques Grand Public) for the European self-medi-
cation industry [19]] or they are declarative data from
patients themselves revealed by some opinion surveys. In
France, the use of drugs available without medical order
is lower than in other countries, being about 8 % of
revenue and 17 % of sale units [19]. Additionally, the
frequency of declared self-medication is about 80 %
among people interviewed by opinion survey promoted
by pharmaceutical manufacturers [22], which is in line
with our results. Several risks are related to self-medi-
cation, of which ADRs are a part. Self-medication is also
associated with diagnostic risks, because the treatment of
symptoms could be delayed before visiting a physician or
the clinical setting could be modified enough to lead the
physician to a medical error. Other risks should also be
considered in the overall management of self-medication,
such as exacerbation of psychiatric diseases [23, 24] and
addiction to drugs [25]. Strategies to control and to
minimize the risk of self-medication should involve
monitoring systems, the promotion of education and
information, and a partnership between patients, physi-
cians and pharmacists [26, 27].
The context and objectives of this study have generated
some bias that requires discussion. Because of the focus of
this study, the self-medication behaviours are explored by
self-report, restricting those enrolled to patients able to
answer the standardized questionnaire. Therefore, the
sample of included patients could not exactly represent the
entire ED population, particularly along the lines of the
severity of illness. Moreover, the collection of declarative
data could lead to recall and reporting bias. The known
discrepancies in self-medication access, depending on local
rules and on the financial ability of patients to pay for their
drugs, could also have influenced our results. Despite these
recognized limits, the overall quality of this survey renders
our results strong enough to be considered as quantitative
of the frequency of ADR-SM in patients admitted to the
ED.
5 Conclusion
Self-medication could lead to the alteration of individual’s
health status in about 1 % of the population reporting self-
medication behaviours, as shown here in the ED popula-
tion. This first result of frequency and severity of ADRs
related to self-medication should lead to further studies
beyond the ED population. The misuse of self-medication
in the general population and its potential impact on the
occurrence of ADRs has to be further explored. Before
considering self-medication as a safe and economic method
of care, the reality of the risk related to self-medication
should be taken into account by healthcare professionals
and institutions. In addition, prevention strategies should
include all aspects of self-medication (including self-use of
prescribed drugs), which must be re-configured to make
self-medication a valuable way of care involving all con-
cerned, including patients and healthcare professionals.
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